KBKatie Beleznay

Katie Beleznay

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katie Beleznay has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Global Survey of Skin Concerns and Treatment Interests in Perimenopausal and Menopausal Patients

    by Sabrina G. Fabi, Andreas Nikolis, Alessandra Haddad, Luiz Avelar, Katie Beleznay, Doris Day, Steven Dayan, Stephanie Lam, Michael Somenek, Neha Sarcevic, et al.

    OBJECTIVE: To explore factors affecting women undergoing menopause transition, focusing on lifestyle, facial-skin changes, and current aesthetic treatment interests for this. METHODS: Quantitative research (online questionnaire) was undertaken by women aged 45 to 60 years from 9 countries to understand their menopause experiences, determine their level of knowledge and perceptions of menopause, and to gain further insights into their current skin care, as well as understand menopause-related skin changes and skin concerns. RESULTS: Across 4,303 respondents, perimenopause and menopause affected facial wrinkles/fine lines (59%), loss of firmness/elasticity (58%), increased dryness (56%), and duller skin tone (40%), which negatively impacted perceived attractiveness (60% agreed/strongly agreed), creating anxiety or low mood (57% agreed/strongly agreed) and impacting self-confidence (55%). The most common treatments to reduce effects of perimenopause and menopause were food supplements (51%), everyday skincare (47%), and dietary changes (46%). Only 15% of the women used specialist aesthetic treatments for menopause, but 88% of them were satisfied/very satisfied with these treatments reducing the effects of menopause. The main triggers that encouraged the respondents to seek aesthetic treatments were health care professionals’ (HCPs) recommendation (46%), cost-related affordability (40%), and information/education (40%). CONCLUSION: This international survey demonstrated that changes to facial skin during perimenopause and menopause negatively affect perceived facial attractiveness, creating anxiety and reducing self-confidence. Specialist aesthetic treatments might play a key role in reducing the effects of menopause on the skin, with health care professionals aiding understanding.

  • From Bruising to Blindness: A Practical Guide to Identifying and Managing Hyaluronic Acid Filler Complications

    by Payvand Kamrani, Sue Ellen Cox, Katie Beleznay, Shannon Humphrey

    PURPOSE: To provide a comprehensive, evidence-based review of the complications associated with hyaluronic acid (HA) dermal fillers and to offer practical guidance for their identification, prevention, and management. DESIGN: Narrative review of the peer-reviewed literature, consensus guidelines, and postmarket surveillance data addressing the classification, pathophysiology, prevention, and treatment of HA filler complications. FINDINGS: Hyaluronic acid fillers carry a favorable safety profile, with severe complications reported in fewer than 0.01% of injection sites. Complications are classified by onset. Early-onset events include ecchymosis, injection-site and hypersensitivity reactions, product displacement, and vascular occlusion. Late-onset events include biofilm-associated infection, delayed inflammatory nodules, granulomas, and hyperpigmentation. Vascular occlusion is the most feared complication and may progress to skin necrosis, vision loss, or stroke; prompt recognition and high-dose hyaluronidase, increasingly aided by ultrasound guidance, are central to management. Prevention rests on sound anatomic knowledge, appropriate product selection, and careful injection technique, while treatment is tailored to the specific complication. SUMMARY: As filler use continues to expand, clinicians must be prepared to recognize, prevent, and manage the full spectrum of complications. This review consolidates current evidence into a practical framework intended to support safe practice and optimal patient outcomes.


  • Open Access

    Poly-L-lactic Acid (Sculptra®): A Regenerative Aesthetic Treatment

    by Sabrina G. Fabi, Alessandra Haddad, Luiz Avelar, Michael Somenek, Katie Beleznay, Steven Dayan, Kathryn Taylor-Barnes, Jeff Huang, Alan D. Widgerow, Matthew Meckfessel, et al.

    Regenerative medicine aims to restore the structure and function for improved tissue health; reduced tissue health can arise from causes such as aging, which results in the ongoing degradation of the extracellular matrix (ECM) of the skin. Replacement of a single biological component is not sufficient for an esthetic treatment to be described as regenerative; it is the relative amounts, ratios, types and organization of stimulated components that are important in a treatment’s regenerative potential. Regenerative aesthetics aims to recapture the youthful structure and function of tissue by exploiting the body’s own systems. Poly-L-lactic acid (PLLA-SCA; Sculptra®), an injectable, biodegradable, non-permanent biostimulator, induces a combination of mechanotransductional/mechanical stimulation and foreign body reaction response and promotes ECM remodeling via the production of collagen through the upregulation of cytokines interleukin-1b and CXCL6, elastin, proteoglycans and multiadhesive glycoproteins. In addition, PLLA-SCA stimulates adipocyte rejuvenation/adipogenesis and increases the thickness of the dermis and adipose layers. Hence, PLLA-SCA stimulates endogenous pathways, and the array of biostimulatory effects should not be considered individually but as interlinked with the overall goal of improvement in skin health. These effects manifest clinically as long-term improvements in the mechanical properties of the skin, the restoration of volume and elasticity, improvements in skin quality and thickness, and dermal remodeling.

  • Open Access

    Physicochemical Properties of Two Poly-L-Lactic Acid Injectable Implants: Potential Impact on Their Biological Properties

    by Luiz Avelar, Alessandra Haddad, Sabrina G. Fabi, Michael Somenek, Katie Beleznay, Shino Bay Aguilera, Kathryn Taylor-Barnes, Cheri Mao, Åke Öhrlund, Björn Lundgren, et al.

    This study evaluated the thermal properties, crystallinity, particle size, morphology, and in vivo local inflammation and persistence of two poly-L-lactic acid (PLLA) injectable implants, Sculptra® (PLLA-SCA) and GANA V® (PLLA-GA). PLLA-SCA and PLLA-GA underwent differential scanning calorimetry and X-ray powder diffraction to evaluate their thermal properties and degree of crystallinity. X-ray powder diffraction spectra displayed a sharper, more intense peak for PLLA-GA than PLLA-SCA, with smaller peaks on either side of the main peak of PLLA-GA but not PLLA-SCA. Differential scanning calorimetry thermograms indicated three thermal events for both PLLA-SCA and PLLA-GA. For PLLA-SCA, the first two events occurred between 65 °C and 90 °C, and the third event occurred at 165 °C. For PLLA-GA all three events occurred between 156 °C and 169 °C. Heating samples to 120 °C and cooling to room temperature prior to differential scanning calorimetry resulted in no thermal events being observed between 65–90 °C with either product, while three events were observed with PLLA-GA and one event with PLLA-SCA between 156 °C and 169 °C. The median volume distribution diameter was 46.4 µm for PLLA-SCA and 31.7 µm for PLLA-GA. Scanning electron microscopy showed PLLA-GA particles were irregular in shape, had no sharp edges and had a wrinkled and crimped surface, while PLLA-SCA particles displayed plate-like shapes and had smoother surfaces. In vivo inflammatory reactivity scores indicated a slight reaction for PLLA-SCA at all time points (3.7 ± 1.1, 6.1 ± 1.6, 5.7 ± 1.2 and 6.2 ± 1.2 at 2, 12, 26 and 52 weeks, respectively), while for PLLA-GA, a moderate reaction was observed at 12 and 26 weeks (2.9 ± 1.5, 10.1 ± 1.0, 9.4 ± 0.7 and 7.1 ± 1.3 at 2, 12, 26 and 52 weeks, respectively). PLLA-SCA and PLLA-GA had similar persistence scores at 2, 12 and 26 weeks, while at 52 weeks the score was markedly higher for PLLA-SCA versus PLLA-GA (1.9 ± 0.2 versus 0.7 ± 0.2). In conclusion, PLLA-SCA is more amorphous than PLLA-GA. The single melting point of PLLA-SCA contrasts with the broader spectrum of melting points for PLLA-GA suggests a more homogenous formulation of PLLA-SCA. This, and its less crystalline structure, result in the slower degradation rate and more sustained biological response of PLLA-SCA compared with PLLA-GA. The physiochemical properties of PLLAs affect the biological response in clinical practice and should be taken into consideration when selecting a PLLA treatment for aesthetic use.


  • Open Access

    Physicochemical Properties of Two Poly-L-Lactic Acid Injectable Implants: Potential Impact on Their Biological Properties

    by Luiz Avelar, Alessandra Haddad, Sabrina G Fabi, Michael Somenek, Katie Beleznay, Shino Bay Aguilera, Kathlyn Taylor-Barnes, Peter Morgan, Cheri Mao, Åke Öhrlund, et al.

    The objective of this study was to evaluate thermal properties and crystallinity of two poly-L-lactic acid (PLLA) injectable implants, Sculptra® (PLLA-SCA) and GANA V® (PLLA-GA), and the extent to which these properties might impact their biological response. PLLA-SCA and PLLA-GA (800mg/sample) underwent differential scanning calorimetry and X-ray powder diffraction to evaluate their thermal properties and degree of crystallinity. X-ray powder diffraction spectra displayed a sharper, more intense peak for PLLA-GA than PLLA-SCA, with smaller peaks on either side of the main peak of PLLA-GA but not PLLA-SCA. Differential scanning calorimetry thermograms indicated three thermal events for both PLLA-SCA and PLLA-GA. For PLLA-SCA, the first two events occurred between 65°C and 90°C and the third event occurred at 165°C. For PLLA-GA all three events occurred between 156°C and 169°C. Heating samples to 120°C and cooling to room temperature prior to differential scanning calorimetry resulted in no thermal events being observed between 65–90°C with either product, while three events were observed with PLLA-GA and one event with PLLA-SCA between 156°C and 169°C. In conclusion, PLLA-SCA is more amorphous than PLLA-GA. The single melting point of PLLA-SCA contrasts with the broader spectrum of melting points for PLLA-GA suggests a more homogenous formulation of PLLA-SCA. This, and its less crystalline structure, result in the slower degradation rate and more sustained biological response of PLLA-SCA compared with PLLA-GA. The physiochemical properties of PLLAs affect the biological response in clinical practice and should be taken into consideration when selecting a PLLA treatment for aesthetic use.


  • Top Cited Papers

    Update on Blindness From Filler: Review of Prognostic Factors, Management Approaches, and a Century of Published Cases

    by Valerie C Doyon, Chaocheng Liu, Rebecca Fitzgerald, Shannon Humphrey, Derek Jones, Jean D A Carruthers, Katie Beleznay

    Vision loss secondary to aesthetic filler treatment is a rare but disastrous complication. The aim was to update the published cases of blindness after filler injection that have occurred since our group published reviews of 98 cases in 2015 and an additional 48 cases in 2019. A literature review was performed to identify all cases of visual complications caused by filler injection published between September 2018 and March 2023. The cases were analyzed independently and in combination with previously reviewed cases. Analyses are based on the number of cases with data available. 365 new cases of partial or complete vision loss after filler injection were identified. The sites that were highest risk were the nose (40.6%), forehead (27.7%), and glabella (19.0%). The filler injected was hyaluronic acid in 79.6% of cases. The most common associated signs were ptosis (56.2%), ophthalmoplegia (44.1%), pain (31.2%), and skin changes (73.2%). Stroke-like features were seen in 19.2% of cases. Of the cases reporting visual outcomes (318), 6.0% experienced complete vision recovery, 25.8% had partial improvement in visual acuity, and 68.2% had no vision recovery. Partially preserved visual acuity at onset was a significant predictor of visual improvement (p < .001). The three most common treatments were subcutaneous hyaluronidase at or near the filler site (70.1%), systemic steroids (57.3%), and intra-arterial thrombolytic therapy (56.0%). No treatments were significantly associated with visual improvement (p > .05). Although blindness and stroke from fillers is a rare complication, practitioners who inject filler should have a thorough knowledge of prevention and management strategies.


  • Response to “Comments on ‘Update on Avoiding and Treating Blindness From Fillers: A Recent Review of the World Literature’”

    by Katie Beleznay, Shannon Humphrey, Jean D A Carruthers, Alastair Carruthers, Derek Jones

    We thank Dr Won Lee for his comments 1 and information he provided about the possible overlap of cases between the 3 articles: “Iatrogenic Occlusion of the Ophthalmic Artery After Cosmetic Facial Filler Injections: A National Survey by the Korean Retina Society” by Park et al,2 “Ophthalmoplegia as a Complication of Cosmetic Facial Filler Injection” by Kim et al,3 and “The Classification and Prognosis of Periocular Complications Related to Blindness Following Cosmetic Filler Injection” by Myung et al.4 Dr Lee highlights that the 3 reports were written by researchers in different departments of the same hospital and so the possibility of overlap between the cases exists.


  • Top Cited Papers

    Update on Avoiding and Treating Blindness From Fillers: A Recent Review of the World Literature

    by Katie Beleznay, Jean D A Carruthers, Shannon Humphrey, Alastair Carruthers, Derek Jones

    Background: Sudden loss of vision secondary to filler treatments is a rare but catastrophic complication. Objectives: The aim of this study was to update the published cases of blindness after filler injection that have occurred since we published our review of 98 cases in 2015, and to discuss prevention and management strategies. Methods: A literature review was performed to identify all cases of visual complications caused by filler injection identified between January 2015 and September 2018. Results: Forty-eight new published cases of partial or complete vision loss after filler injection were identified. The sites that were highest risk were the nasal region (56.3%), glabella (27.1%), forehead (18.8%), and nasolabial fold (14.6%). Hyaluronic acid filler was the cause of this complication in 81.3% of cases. Vision loss, pain, ophthalmoplegia, and ptosis were the most common reported symptoms. Skin changes were seen in 43.8% of cases and central nervous system complications were seen in 18.8% of cases. Ten cases (20.8%) experienced complete recovery of vision, whereas 8 cases (16.7%) reported only partial recovery. Management strategies varied greatly and there were no treatments that were shown to be consistently successful. Conclusions: Although the risk of blindness from fillers is rare, practitioners who inject filler should have a thorough knowledge of this complication including prevention and management strategies. Level of Evidence: 5:


  • Top Cited Papers

    Delayed-Onset Nodules Secondary to a Smooth Cohesive 20 mg/mL Hyaluronic Acid Filler

    by Katie Md Beleznay, Jean D. A. Md Carruthers, Alastair Ma Carruthers, Mark E. Bs Mummert, Shannon Md Humphrey

    BACKGROUND The shift from 2- to 3-dimensional soft tissue augmentation has allowed the development of hyaluronic acid (HA) fillers, which are long lasting and also reversible. Delayed-onset inflammatory nodules have recently been reported with the use of HA fillers. OBJECTIVE The authors document their experience with delayed-onset nodules after 3-dimensional facial injection of Juvéderm Voluma (HA-V) over 68 months. MATERIALS AND METHODS The authors conducted a retrospective chart review of patients who were treated with HA-V between February 1, 2009, and September 30, 2014, to evaluate for delayed-onset nodules. RESULTS Over 68 months, 4,702 treatments were performed using 11,460 mL of HA-V. Twenty-three patients (0.5%) experienced delayed-onset nodules. The median time from injection to reaction was 4 months, and median time to resolution was 6 weeks. Nine of the 23 (39%) had an identifiable immunologic trigger such as flu-like illness before the nodule onset. In the authors' experience, prednisone, intralesional corticosteroids, and hyaluronidase were effective treatments. CONCLUSION Although delayed nodules are uncommon from HA-V (0.5%), it is important to be aware of this adverse effect and have a management protocol in place. It is the authors' opinion from the patients' responses and from the literature that these nodules are immune mediated in nature.


  • Lupus miliaris disseminatus faciei treated with 1,565 nm nonablative fractionated laser resurfacing: A case report

    by Katie Beleznay, Daniel P. Friedmann, Ana Marie Liolios, Adam Perry, Mitchel P. Goldman

    Background: Lupus miliaris disseminatus faciei (LMDF) is a rare granulomatous disease. It presents as red‐brown papules on the face that can resolve with scarring. LMDF is often resistant to treatment.Objective: Nonablative fractionated lasers have been used effectively to treat granulomatous disorders; however, there is little data on the treatment of LMDF with lasers. Our objective was to test a novel non‐ablative fractionated laser for the treatment of recalcitrant LMDF.Results: A 24‐year‐old man had a one‐year history of LMDF. He had been treated with various topical therapies, oral medications, and laser devices with no improvement and continued progression. We utilized a non‐sequential scanning 1,565 nm nonablative fractionated laser to treat this patient. After only one treatment he had significant improvement. He has been subsequently treated five times in the past 6 months and has continued to improve.Conclusion: The novel 1,565 nm nonablative fractionated laser may be a useful tool in the treatment of granulomatous conditions such as LMDF. Lasers Surg. Med. 46:663–665, 2014.